Reuters
21 Jul 2026, 20:44 UTC · 2h ago
Celldex to stop skin disease study after trial setback
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
Reuters
21 Jul 2026, 20:44 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
What the story claims
1 claim · each scored for market impact
Celldex Therapeutics is discontinuing the development of its experimental skin disease drug after it failed to meet primary and key secondary goals in a mid-stage study. — The complete abandonment of a drug candidate due to failure in clinical trials represents a total loss of potential future revenue and R&D investment.
-0.80Which stocks this story touches
The company is discontinuing an experimental drug after it failed to meet goals in a mid-stage study, leading to a share price drop.
Continue reading
6 related stories
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
11h ago
